Last reviewed · How we verify

NCT04551391: KRAKIL

Kidney Recovery After Acute Kidney Injury - Longitudinal Study

Completed Last updated 15 November 2023
What this trial tests

trial testing Blood and urine sampling in Acute Kidney Injury in 100 participants. Completed in 1 November 2023.

Timeline
7 January 2020
Primary endpoint
1 November 2023
1 November 2023

Quick facts

Lead sponsorNHS Lothian
StatusCompleted
Study typeOBSERVATIONAL
Enrollment100
Start date7 January 2020
Primary completion1 November 2023
Estimated completion1 November 2023
Sites1 location across United Kingdom

Drugs / interventions tested

Conditions studied

Sponsor

NHS Lothian — full company profile →

Who can join

16 and older, any sex, with Acute Kidney Injury or Chronic Kidney Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The endothelin (ET) system is an active target in human Acute Kidney Injury (AKI). Our primary hypothesis is that the circulating blood concentration of ET will be higher in patients with AKI than in matched controls.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Blood and urine sampling

Trials testing the same drug.

Other recruiting trials for Acute Kidney Injury

Currently open trials in the same condition.

Other NHS Lothian trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04551391.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing